See more : Exicom Tele-Systems Limited (EXICOM.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Sientra, Inc. (SIEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sientra, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Enterprise Products Partners L.P. (0S23.L) Income Statement Analysis – Financial Results
- Gold Line International Finvest Limited (GOLDLINE.BO) Income Statement Analysis – Financial Results
- PT Medikaloka Hermina Tbk (HEAL.JK) Income Statement Analysis – Financial Results
- T.RAD Co., Ltd. (7236.T) Income Statement Analysis – Financial Results
- XP Inc. (XPVVV) Income Statement Analysis – Financial Results
Sientra, Inc. (SIEN)
About Sientra, Inc.
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.55M | 80.68M | 71.24M | 83.70M | 68.13M | 36.54M | 20.73M | 38.11M | 44.73M | 35.17M | 10.45M |
| Cost of Revenue | 48.96M | 36.35M | 32.30M | 33.01M | 26.82M | 14.17M | 6.88M | 10.65M | 11.50M | 8.59M | 2.35M |
| Gross Profit | 41.59M | 44.34M | 38.94M | 50.69M | 41.30M | 22.37M | 13.85M | 27.45M | 33.23M | 26.58M | 8.10M |
| Gross Profit Ratio | 45.94% | 54.95% | 54.66% | 60.56% | 60.63% | 61.22% | 66.82% | 72.04% | 74.29% | 75.57% | 77.49% |
| Research & Development | 14.06M | 10.46M | 10.31M | 13.54M | 10.95M | 9.81M | 9.70M | 7.20M | 4.71M | 4.48M | 3.67M |
| General & Administrative | 41.53M | 31.77M | 38.19M | 46.77M | 42.42M | 41.54M | 23.58M | 18.74M | 10.71M | 18.08M | 9.94M |
| Selling & Marketing | 55.05M | 48.46M | 52.55M | 80.19M | 67.72M | 33.91M | 20.61M | 25.76M | 23.60M | 22.23M | 17.92M |
| SG&A | 96.58M | 80.23M | 90.74M | 126.96M | 110.13M | 75.45M | 44.18M | 44.50M | 34.31M | 40.31M | 27.86M |
| Other Expenses | 12.00K | 6.56M | 111.00K | -55.00K | 39.00K | -95.00K | -36.00K | 360.00K | 2.15M | -46.00K | -1.00K |
| Operating Expenses | 110.64M | 90.69M | 101.06M | 140.50M | 121.08M | 85.26M | 53.89M | 51.70M | 39.02M | 44.79M | 31.53M |
| Cost & Expenses | 159.60M | 127.03M | 133.36M | 173.51M | 147.90M | 99.43M | 60.77M | 62.35M | 50.52M | 53.38M | 33.88M |
| Interest Income | 130.00K | 4.00K | 206.00K | 1.41M | 532.00K | 172.00K | 63.00K | 32.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.53M | 8.25M | 9.45M | 4.57M | 3.43M | 1.23M | 98.00K | 3.10M | 2.17M | 872.00K | 0.00 |
| Depreciation & Amortization | 6.78M | 10.93M | 4.41M | 9.05M | 3.32M | 3.03M | 1.18M | 318.00K | 275.00K | 280.00K | 288.00K |
| EBITDA | -62.27M | -46.35M | -70.31M | -103.57M | -75.88M | -59.78M | -38.48M | -38.53M | -3.64M | -17.97M | -23.15M |
| EBITDA Ratio | -68.77% | -43.91% | -81.00% | -96.49% | -111.38% | -163.59% | -192.95% | -62.60% | -8.13% | -51.10% | -221.55% |
| Operating Income | -69.05M | -46.35M | -62.12M | -89.81M | -79.77M | -62.89M | -40.03M | -38.53M | -5.79M | -18.21M | -23.43M |
| Operating Income Ratio | -76.26% | -57.45% | -87.19% | -107.30% | -117.10% | -172.10% | -193.08% | -101.10% | -12.93% | -51.77% | -224.29% |
| Total Other Income/Expenses | -4.23M | -16.15M | -4.96M | -16.97M | -2.86M | -1.16M | -71.00K | -2.71M | -26.00K | -918.00K | -1.00K |
| Income Before Tax | -73.69M | -62.50M | -89.91M | -106.78M | -82.63M | -64.05M | -40.11M | -41.23M | -5.81M | -19.13M | -23.43M |
| Income Before Tax Ratio | -81.38% | -77.46% | -126.21% | -127.58% | -121.29% | -175.26% | -193.43% | -108.20% | -12.99% | -54.38% | -224.30% |
| Income Tax Expense | 27.00K | 21.00K | 33.00K | 34.00K | -4.00K | -17.00K | 61.00K | 3.14M | 4.04M | 826.00K | -1.00K |
| Net Income | -73.72M | -62.52M | -89.95M | -106.82M | -82.63M | -64.03M | -40.17M | -41.23M | -5.81M | -19.13M | -23.43M |
| Net Income Ratio | -81.41% | -77.49% | -126.26% | -127.62% | -121.29% | -175.22% | -193.72% | -108.20% | -12.99% | -54.38% | -224.30% |
| EPS | -10.27 | -10.96 | -17.91 | -26.27 | -32.53 | -33.42 | -22.03 | -26.14 | -22.83 | -20.90 | -25.61 |
| EPS Diluted | -10.27 | -10.96 | -17.91 | -26.27 | -32.53 | -33.42 | -22.03 | -26.14 | -22.83 | -20.90 | -25.61 |
| Weighted Avg Shares Out | 7.17M | 5.71M | 5.02M | 4.07M | 2.54M | 1.92M | 1.82M | 1.58M | 254.54K | 915.12K | 915.12K |
| Weighted Avg Shares Out (Dil) | 7.18M | 5.71M | 5.02M | 4.07M | 2.54M | 1.92M | 1.82M | 1.58M | 254.54K | 915.12K | 915.12K |
3 Penny Stocks Investors Are Betting On Big For A Downfall
Penny stocks with unusual options volume in the stock market today. The post 3 Penny Stocks Investors Are Betting On Big For A Downfall appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
See Why Did Stifel, Maxim Cut Price Target On Sientra After Q4 Earnings
Maxim lowered the price target on Sientra Inc (NASDAQ: SIEN) to $7 from $13 but kept a Buy rating on the stock. Analyst Anthony Vendetti notes that the Company's Q4 revenue was in-line with its pre-announcement in January, but gross margin was below...
Sientra (SIEN) Reports Q4 Loss, Tops Revenue Estimates
Sientra (SIEN) delivered earnings and revenue surprises of -42.11% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sientra, Inc. (SIEN) CEO Ron Menezes on Q4 2021 Results - Earnings Call Transcript
Sientra, Inc. (SIEN) CEO Ron Menezes on Q4 2021 Results - Earnings Call Transcript
Is a Surprise Coming for Sientra (SIEN) This Earnings Season?
Sientra (SIEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sientra to Report Fourth Quarter and Full Year 2021 Financial Results on March 23, 2022
SANTA BARBARA, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results...
Sientra to Present at the H.C. Wainwright Bioconnect Virtual Conference
SANTA BARBARA, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that members of management will present...
Sientra, Inc. (SIEN) CEO Ron Menezes on Q3 2021 Results - Earnings Call Transcript
Sientra, Inc. (SIEN) CEO Ron Menezes on Q3 2021 Results - Earnings Call Transcript
Sientra (SIEN) Reports Q3 Loss, Tops Revenue Estimates
Sientra (SIEN) delivered earnings and revenue surprises of -153.85% and 8.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
New Study Confirms Sientra's AlloX2's Unique Value in Managing Seroma and Infection Post Reconstruction Procedures
SANTA BARBARA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgery, today announced that a recent independent study out of Stanford University's School of Medicine, published...
Source: https://incomestatements.info
Category: Stock Reports